Royalty Pharma plc (RPRX) FY2026 YTD Q2 P&L / Income Statement

Royalty Pharma plc (RPRX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total income and other revenues

1,304,717,000 US dollars

Total operating expense, net

608,561,000 US dollars

Operating income

696,156,000 US dollars

Total other expense, net

negative 146,415,000 US dollars

Consolidated net income before tax

549,741,000 US dollars

Income tax expense

0 US dollars

Consolidated net income

549,741,000 US dollars

Income from financial royalty assets

1,233,019,000 US dollars

Other royalty income and revenues

71,698,000 US dollars

Provision for changes in expected cash flows from financial royalty assets

70,732,000 US dollars

Provision for credit losses on unfunded commitments

9,368,000 US dollars

Research and development funding expense

137,641,000 US dollars

General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4)

321,377,000 US dollars

Financial royalty asset impairment

69,443,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Royalty Pharma plc: $312.57 M; to noncontrolling interests: $237.17 M.